Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

When should ranolazine be considered for the treatment of chronic angina?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 590–591 (2006)Cite this article

boxed-textStone PH et al. (2006) Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48: 566–575

Ranolazine should be considered in patients with chronic angina that remains symptomatic when β-blockers, calcium antagonists or nitrates are administered

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chaitman BR (2006) Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113: 2462–2472

    Article  Google Scholar 

  2. Belardinelli L et al. (2006) The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 8: A10–A13

    Article  CAS  Google Scholar 

  3. Antzelevitch C et al. (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904–910

    Article  CAS  Google Scholar 

  4. MacInnes A et al. (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93: e26–e32

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Carol Lovegrove, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. Professor of Medicine and Director of Cardiovascular Research at St Louis University School of Medicine, St Louis, MO, USA

    Bernard R Chaitman

Authors
  1. Bernard R Chaitman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard R Chaitman.

Ethics declarations

Competing interests

Dr Chaitman is a consultant and received research grants from CV Therapeutics, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaitman, B. When should ranolazine be considered for the treatment of chronic angina?. Nat Rev Cardiol 3, 590–591 (2006). https://doi.org/10.1038/ncpcardio0686

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0686

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing